This presentation will highlight a preclinical dataset that provides insights into the role of inhibiting TGF-β in overcoming acquired KRAS-G12C-inhibitor drug-resistant KRAS-G12C-mutated lung cancer.

New research led by American Cancer Society (ACS) researchers estimates more than 3.8 million lung cancer deaths were averted ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bernstein Liebhard LLP:Do you, or did you, own shares of Intellia Therapeutics, Inc.

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

Beam Therapeutics announced positive initial data for BEAM-302 in the Phase I/II trial in Alpha-1 Antitrypsin Deficiency (AATD).

Ongoing clinical trials to develop a lung cancer vaccine to treat or prevent ... who’s the director of thoracic oncology and developmental therapeutics at Georgetown’s Lombardi Comprehensive ...

Beam Therapeutics said Monday that it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a debilitating lung condition that may affect tens of ...

solid tumors like lung and colorectal cancers have proven to be resistant to current CAR T therapies", said Jeff Liter, CEO and President of Luminary Therapeutics. "This project combines an ...

Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a ...